Christine Houlihan

Effects of Salt Supplementation on the Albuminuric Response to Telmisartan With or Without Hydrochlorothiazide Therapy in Hypertensive Patients With Type 2 Diabetes Are Modulated by Habitual Dietary Salt Intake

OBJECTIVE This prospective randomized double-blind placebo-controlled crossover study examined the effects of sodium chloride (NaCl) supplementation on the antialbuminuric action of telmisartan with or without hydrochlorothiazide (HCT) in hypertensive patients with type 2 diabetes, increased albumin excretion rate (AER), and habitual low dietary salt intake (LDS; <100 mmol sodium/24 h on two of three consecutive occasions) or high dietary salt intake (HDS; >200 mmol sodium/24 h on two of three consecutive occasions). RESEARCH DESIGN AND METHODS Following a washout period, subjects (n = 32) received 40 mg/day telmisartan for 4 weeks followed by 40 mg telmisartan plus 12.5 mg/day HCT for 4 weeks. For the last 2 weeks of each treatment period, patients received either 100 mmol/day NaCl or placebo capsules. After a second washout, the regimen was repeated with supplements in reverse order. AER and ambulatory blood pressure were measured at weeks 0, 4, 8, 14, 18, and 22. RESULTS In LDS, NaCl supplementation reduced the anti-albuminuric effect of telmisartan with or without HCT from 42.3% (placebo) to 9.5% (P = 0.004). By contrast, in HDS, NaCl supplementation did not reduce the AER response to telmisartan with or without HCT (placebo 30.9%, NaCl 28.1%, P = 0.7). Changes in AER were independent of changes in blood pressure. CONCLUSIONS The AER response to telmisartan with or without HCT under habitual low salt intake can be blunted by NaCl supplementation. By contrast, when there is already a suppressed renin angiotensin aldosterone system under habitual high dietary salt intake, the additional NaCl does not alter the AER response.

Challenging the glucose challenge test

Background:  To reduce the number of patients needing oral glucose tolerance test (OGTT), screening options have been considered, balancing patient comfort, cost and risk of missed diagnosis. Australian Diabetes in Pregnancy Society (ADIPS) recommends glucose challenge test (GCT) as screening for gestational diabetes mellitus (GDM), while others suggest fasting plasma glucose (FPG). International Association of Diabetes and Pregnancy Study Group (IADPSG) recently recommended new diagnostic criteria for GDM using one‐step OGTT.

Measurement of Iohexol by Capillary Electrophoresis: Minimizing Practical Problems Encountered:

Iohexol is a non-ionic contrast agent, which has been widely described in recent literature as an accurate marker for the measurement of glomerular filtration rate (GFR). Our aim was to establish a capillary electrophoresis assay, based on a previously described method, that had adequate reproducibility to be used as part of a clinical trial. In this paper, we examine the practical aspects, pitfalls and steps we took to achieve a precise and reproducible assay. To minimize laboratory variation, we examined properties such as the use of an internal standard in a capillary electrophoresis separation, alternative deproteinization methods for serum, the most suitable matrix for the dilution of standards and the implementation of suitable quality control material to ensure that run-to-run variability was minimized. The optimized capillary electrophoretic assay of iohexol was found to be robust, with over 860 runs from the one capillary over a 9-month period. Excluding capital costs of the instrument, the consumable cost of the assay is less than AS0·25 per test, with a run time of 5·25 min and a coefficient of variation (CV) of 4·3% at 80 mg/L. The GFR, calculated from the plasma clearance, had a reproducibility of 5·47%.

Longitudinal assessment of thyroid function in pregnancy

Background Trimester-specific reference intervals (RIs) for thyroid function tests are lacking for Beckman Dxl 800 analysers. We aimed to establish RIs for thyroid stimulating hormone (TSH), free thyroxine (fT4) and to track intraindividual changes in thyroid function throughout pregnancy. Methods One hundred and thirty healthy women without antithyroid peroxidase antibodies were followed longitudinally. Thyroid function was determined at trimester-1 (T1): 9–13 weeks; trimester-2 (T2): 22–26 weeks; trimester-3 (T3): 35–39 weeks and postpartum (PP): 8–12 weeks. A subgroup (n = 47) was used to track intraindividual changes using PP as non-pregnant state (baseline). Results For trimesters 1–3, TSH (median (2.5th, 5th, 95th and 97.5th percentile)) was 0.77 (0.03, 0.05, 2.33, 3.05), 1.17 (0.42, 0.47, 2.71, 3.36) and 1.35 (0.34, 0.42, 2.65, 2.83) mIU/L, respectively. Free T4 (mean (95%CI)) was 10.7 (5.9–15.5), 8.1 (4.9–11.3), 7.8 (4.5–11.0) pmol/L, respectively. In T2 and T3, 36% and 41% of the fT4 values, respectively, fell below the non-pregnancy lower normal limit. In the subgroup assessed for longitudinal changes, of the women with baseline TSH ⩽ median, 71–75% remained at or below the corresponding median for trimesters 1–3. Of the women with baseline fT4 ⩽ median, 69–81% also remained at or below the corresponding median for trimesters 1–3. High correlation was observed at different trimesters and baseline for TSH (Spearman’s r: 0.593–0.846, P < 0.001) and for fT4 (r: 0.480–0.739, P < 0.001). Conclusions Use of trimester-specific RIs would prevent misclassification of thyroid function during pregnancy. In the majority of women, TSH and fT4 tracked on the same side of the median distribution, from a non-pregnant baseline, throughout pregnancy.

Review of 3-year outcomes of a very-low-energy diet-based outpatient obesity treatment programme.

Obesity is a complex disorder that requires a multidisciplinary treatment approach. This review evaluated 3‐year outcomes of a very‐low‐energy diet (VLED)‐based programme at a tertiary hospital multidisciplinary weight management clinic. Medical records of all patients who agreed to undertake the VLED programme and who did not undergo bariatric surgery during the 3‐year follow‐up period were examined. Baseline data collection included demographic and anthropometric characteristics, childhood onset of obesity and co‐existing medical conditions. Weight was modelled using a linear mixed effects analysis. Logistic regression analyses were used to model the probability of continuing to attend the clinic and to identify pre‐treatment factors associated with longer duration of attendance. Data from 1109 patients were included. A total of 231 patients (19.2%) were still attending the clinic 3 years after their initial appointment. Mean weight loss among patients who attended the clinic for 3 years was 6.4 kg (3.5%, 95% confidence interval [CI] 2.8, 4.2%). People who were prescribed pharmacotherapy maintained greater weight loss at 3 years (7.7% vs. 2.3% without pharmacotherapy, 95% CI for difference 3.9, 7.0%). People who had an onset of obesity in childhood, who had co‐existing hypertension or coronary artery disease, and who did not currently smoke were more likely to continue to attend the clinic for up to 3 years. In summary, in an outpatient weight management clinic, patients who undertook a VLED‐based programme and continued in follow‐up achieved a clinically significant weight loss at 3 years, particularly if pharmacotherapy was used for weight loss maintenance.

A longitudinal study of thyroid autoantibodies in pregnancy: the importance of test timing

Thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TGAb) are frequently measured to investigate thyroid dysfunction in pregnancy. Despite the recognized fall of these autoantibodies in pregnancy, there is limited guidance on the timing of such testing. We assessed optimal test timing of TPOAb/TGAb for the detection of Hashimotos thyroiditis and post‐partum thyroid dysfunction (PPTD).

Combination phentermine and topiramate for weight maintenance: the first Australian experience.

Objective: To investigate the safety, tolerability and efficacy of combination phentermine and topiramate therapy for maintenance of weight loss.

Higher maternal serum prolactin levels are associated with reduced glucose tolerance during pregnancy.

It is unknown if high prolactin levels during pregnancy contribute to the development of gestational diabetes. We hypothesized that higher prolactin levels are associated with reduced glucose tolerance, as determined by higher 2‐h glucose level from an oral glucose tolerance test in pregnancy. The 75‐g oral glucose tolerance test was carried out at 28 weeks of gestation in 69 participants. A multiple regression analysis was used to determine the relationship between serum prolactin and 2‐h glucose levels. Multivariable regression analysis showed an independent and significant relationship between third trimester prolactin and 2‐h glucose levels post oral glucose tolerance test. Higher prolactin levels were associated with higher glucose levels independent of age, body mass index, gravidity and parity. Higher prolactin levels associated with reduced glucose tolerance in the third trimester of pregnancy suggests the possible independent role of prolactin in the pathogenesis of gestational diabetes.

Timing of diagnosis of gestational diabetes and pregnancy outcomes: A retrospective cohort

Recent guidelines suggest screening high‐risk women in early pregnancy for gestational diabetes (GDM); however, there is little evidence to support this.

Rare cause of maternal and neonatal hypercalcaemia: Maternal and neonatal hypercalcaemia

Rare cause of maternal and neonatal hypercalcaemia Lucy McBride , Amy Crosthwaite, Christine Houlihan, Zornitza Stark and Christine Rodda Department of Obstetrics and Gynaecology, Mercy Hospital for Women, Victorian Clinical Genetics Services, Royal Children’s Hospital, Department of Paediatrics, University of Melbourne and Australian Institute for Musculoskeletal Research (AIMSS), Sunshine Hospital, Melbourne, Victoria, Australia